Senti Biosciences - רווח נקי למניה ב-12 החודשים האחרונים SNTI

Senti Biosciences, Inc. (SNTI) relies on an allogeneic platform that reduces costs as production volumes scale. The rolling annual EPS YoY trend confirms this resilience, with the metric standing at 79.80. However, the business is burdened by cryogenic transport costs for biomaterials and a dependence on external financing due to a lack of pricing power during early-stage trials.

When screening issuer reliability, it is essential to evaluate the percentage change in net income per share over a rolling year to identify business scaling rates. The year-over-year EPS dynamics over the last 12 months reflect the efficiency of Senti Biosciences (SNTI) in capitalizing on its gene circuit innovations, helping determine whether its unique oncology treatment method is converting into actual financial growth.